Search research articles
Contact Us
Filters
Showing results (71-80 of 367) with videos related to
Page
of 37
Sort By:
Clinical Pharmacology and Therapeutics
|
August 13, 2021
Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"
Stefanie L Groenland, Dieuwertje R Geel, Jos H Beijnen, et al.
Journal of Biomolecular Screening
|
November 1, 2012
Affordable luciferase reporter assay for cell-based high-throughput screening
Ellen Siebring-van Olst, Christie Vermeulen, Renee X de Menezes, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 23, 2016
Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients
Gerbrand Maria Kramer, Virginie Frings, Nikie Hoetjes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
Jens Voortman, Egbert F Smit, Richard Honeywell, et al.
Oncogene
|
February 2, 2019
High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome
Maxime Blijlevens, Ida H van der Meulen-Muileman, Renée X de Menezes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 17, 2009
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity
Joline S W Lind, Pieter E Postmus, Daniëlle A M Heideman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 18, 2008
Reproducibility of tumor perfusion measurements using 15O-labeled water and PET
Adrianus J de Langen, Mark Lubberink, Ronald Boellaard, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 28, 2011
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
Floris H P van Velden, Patsuree Cheebsumon, Maqsood Yaqub, et al.
Expert Review of Anticancer Therapy
|
February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i>-mutant NSCLC: a bench-to-bedside review
John V Heymach, Sanjay Popat, Egbert F Smit, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 11, 2013
Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery
Gwendolyn H M J Griffioen, Frank J Lagerwaard, Cornelis J A Haasbeek, et al.
Page
of 37
Search research articles
Search
Showing results (71-80 of 367) with videos related to
Sort By:
Page
of 37
Clinical Pharmacology and Therapeutics
|
August 13, 2021
Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"
Stefanie L Groenland, Dieuwertje R Geel, Jos H Beijnen, et al.
Journal of Biomolecular Screening
|
November 1, 2012
Affordable luciferase reporter assay for cell-based high-throughput screening
Ellen Siebring-van Olst, Christie Vermeulen, Renee X de Menezes, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 23, 2016
Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients
Gerbrand Maria Kramer, Virginie Frings, Nikie Hoetjes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
Jens Voortman, Egbert F Smit, Richard Honeywell, et al.
Oncogene
|
February 2, 2019
High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome
Maxime Blijlevens, Ida H van der Meulen-Muileman, Renée X de Menezes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 17, 2009
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity
Joline S W Lind, Pieter E Postmus, Daniëlle A M Heideman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 18, 2008
Reproducibility of tumor perfusion measurements using 15O-labeled water and PET
Adrianus J de Langen, Mark Lubberink, Ronald Boellaard, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 28, 2011
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
Floris H P van Velden, Patsuree Cheebsumon, Maqsood Yaqub, et al.
Expert Review of Anticancer Therapy
|
February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i>-mutant NSCLC: a bench-to-bedside review
John V Heymach, Sanjay Popat, Egbert F Smit, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 11, 2013
Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery
Gwendolyn H M J Griffioen, Frank J Lagerwaard, Cornelis J A Haasbeek, et al.
Page
of 37